

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY**

IN RE DENOSUMAB PATENT
LITIGATION

This Document Relates To:

*Amgen Inc. et al. v. Hikma Pharmaceuticals
USA Inc. et al.*, Civil Action No. 1:25-cv-
12152 (CPO-EAP)

Civil Action No. 25-md-03138 (CPO) (EAP)
(MDL 3138)

CONSENT JUDGMENT AND INJUNCTION

WHEREAS Amgen Inc. and Amgen Manufacturing Limited (collectively, “Amgen” or “Plaintiffs”), and Hikma Pharmaceuticals USA Inc., Gedeon Richter Plc., Gedeon Richter (Schweiz) AG, and Gedeon Richter USA, Inc. (collectively, “Defendants”) were involved in litigation in the United States District Court for the District of New Jersey, MDL Case No. 1:25-md-03138, associated Case No. 1:25-cv-12152 (CPO) (EAP) (the “Hikma U.S. District Court Litigation”) involving Amgen’s patents covering its denosumab antibody, pharmaceutical compositions containing denosumab, and methods of manufacture, stemming from Hikma’s filing of a BLA seeking FDA approval of Hikma Biosimilar Products;

WHEREAS Amgen and Defendants have reached an agreement to resolve the Hikma U.S. District Court Litigation, executing a Confidential Settlement Agreement (“the Agreement”);

WHEREAS, as a part of the Agreement, the parties agreed that the Court would enter judgment and the injunction set forth below;

WHEREAS the parties have waived the entry of findings of fact and conclusions of law under Rule 65 of the Federal Rules of Civil Procedure.

THEREFORE based on the parties' stipulation and consent, it is ORDERED, ADJUDGED, and DECREED as follows:

1. The Court has jurisdiction over the subject matter of the above-captioned case pursuant to 28 U.S.C. §§ 1331 and 1338(a).

2. The Court has personal jurisdiction over the parties, and venue is proper as to all parties pursuant to 28 U.S.C. §§ 1391(b), (c), and 1400 (b).

3. The Court retains jurisdiction to enforce or supervise performance under this Order and Injunction and the parties' Agreement dated November 21, 2025.

4. Subject to and pursuant to the terms of the Agreement and as to the Hikma Biosimilar Products, the asserted claims of United States Patent Nos. 7,364,736; 7,888,101; 7,928,205; 8,053,236; 8,058,418; 8,460,896; 8,680,248; 9,012,178; 9,228,168; 9,328,134; 9,359,435; 9,371,554; 10,106,829; 10,167,492; 10,227,627; 10,513,723; 10,583,397; 10,822,630; 10,894,972; 11,077,404; 11,098,079; 11,130,980; 11,192,919; 11,254,963; 11,299,760; 11,319,568; 11,434,514; 11,459,595; 11,492,372; 11,946,085; 11,952,605; and 12,084,686 ("Asserted Patents") are valid, enforceable and infringed by the making, using, selling, or offering to sell Hikma Biosimilar Products in the United States of America, its territories, possessions, protectorates and the Commonwealth of Puerto Rico ("United States Territory"), or by the import of Hikma Biosimilar Products into the United States Territory.

5. Subject to and pursuant to the terms of the Agreement, Defendants, including any entity directly or indirectly controlled by, controlling, or under common control with each, their officers, agents and employees, and any third party acting on behalf of or in active concert with each of them are hereby enjoined from making, using, offering to sell, or selling the Hikma Biosimilar Products in the Territory, or importing the Hikma Biosimilar Products into the

Territory, except as permitted under the Agreement, or by 35 U.S.C. § 271(e)(1). The foregoing injunction expires on January 1, 2026.


6. Subject to the terms of the Agreement, the parties' remaining claims and counterclaims in the above-captioned matter are dismissed with prejudice.

7. Judgment is entered with respect to the Asserted Patents, and this order fully resolves the remaining claims and counterclaims.

8. Each party shall bear its own costs.

IT IS SO ORDERED.

Dated: 11/24/2025


Hon. Christine P. O'Hearn
United States District Judge